Tuesday - November 3, 2026
Johnson & Johnson announces ERLEADA(r) (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer
October 24, 2026
NEW BRUNSWICK, New Jersey, Oct. 24 [Category: BizHealth & Beauty] -- Johnson and Johnson posted the following news release:

* * *

Johnson & Johnson announces ERLEADA(r) (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer

*

New Brunswick, N.J. October 24, 2026 /PR Newswire/ - Johnson & Johnson (NYSE:JNJ) today announced new results from the Phas . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products